^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    RNA polymerase inhibitor

    Related drugs:
    4d
    QUANTUM: A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis (clinicaltrials.gov)
    P3, N=532, Recruiting, Otsuka Pharmaceutical Development & Commercialization, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rifampicin
    6d
    INSPIRE-BLMZ: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort (clinicaltrials.gov)
    P3, N=120, Not yet recruiting, Beijing Chest Hospital
    New P3 trial
    |
    rifampicin
    9d
    Silibinin inhibits F-actin assembly leading to G2/M cell cycle arrest in human breast cancer cells - is targeted therapy on the horizon? (PubMed, Biochem Pharmacol)
    Our results reveal the F-actin assembly is inhibited by silibinin, and this results in G2/M cell cycle arrest in human breast cancer cells, providing new ideas for anti-cancer therapies including TNBCs. Abbreviations: ABPs, actin binding proteins; ARP2, actin-related protein2; Capza1, capping actin protein of muscle Z-line subunit alpha 1; CDC2, Cell Division Cycle protein 2/CDK1, Cyclin-Dependent Kinase 1; CDKi, cyclin-dependent kinase inhibitors; CDKs, cyclin-dependent kinases; CETSA, cellular thermal shift assay; CFL1, cofilin 1; Cyto D, Cytochalasin D; DARTS, drug affinity responsive target stability; DIAPH3, diaphanous related formin 3; DMEM, Dulbecco's Modified Eagle medium; ER, estrogen receptor; F-actin, filamentous actin; FBS, fetal bovine serum; G-actin, globular actin; GSN, gelsolin; HER2, human epidermal growth factor receptor 2; LAMP1, lysosomal associated membrane protein 1; NLS, nuclear localization signal; PDB, protein data bank; PFN1, profilin 1; PR, progesterone receptor; qRT-PCR, quantitative real-time polymerase chain reaction; RT, room temperature; Sili, silibinin; si-RNAs, small interfering RNAs; TNBC, triple-negative breast cancer; VP, verteporfin; YAP, Yes-associated protein.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • LAMP1 (Lysosomal Associated Membrane Protein 1) • CDK1 (Cyclin-dependent kinase 1) • ACTR2 (Actin Related Protein 2) • DIAPH3 (Diaphanous Related Formin 3) • GSN (Gelsolin)
    |
    Visudyne (verteporfin)
    12d
    Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sichuan University
    New P2 trial
    |
    albumin-bound paclitaxel • etoposide IV • irinotecan • Zepzelca (lurbinectedin)
    12d
    STRONG: Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov)
    P=N/A, N=110, Recruiting, Istituto Oncologico Veneto IRCCS | Not yet recruiting --> Recruiting
    Enrollment open
    |
    temozolomide
    24d
    Unveiling the therapeutic potential of silibinin in head and neck squamous cell carcinoma via network pharmacology. (PubMed, Sci Rep)
    Our data suggested that silibinin may inhibit HNSCC progression through modulation of the interleukin-17 signaling pathway. Molecular docking confirmed strong binding affinity between silibinin and key targets, supporting its potential as an HNSCC therapeutic agent.
    Journal
    |
    IL17A (Interleukin 17A)
    27d
    Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A (clinicaltrials.gov)
    P3, N=114, Not yet recruiting, Guangdong Raynovent Biotech Co., Ltd
    New P3 trial
    27d
    Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A (clinicaltrials.gov)
    P3, N=150, Recruiting, Guangdong Raynovent Biotech Co., Ltd
    New P3 trial
    27d
    Pharmacokinetics，Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A (clinicaltrials.gov)
    P2, N=72, Completed, Guangdong Raynovent Biotech Co., Ltd | Recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Nov 2025 --> Jun 2025
    Trial completion • Trial completion date • Trial primary completion date
    1m
    OpTION: Optimal Treatment for Recurrent Clostridium Difficile (clinicaltrials.gov)
    P4, N=308, Terminated, VA Office of Research and Development | Completed --> Terminated; The study sponsor stopped the trial early after enrolling 308 of the target sample size because of a slower than expected recruitment rate.
    Trial termination
    1m
    Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease (clinicaltrials.gov)
    P4, N=60, Not yet recruiting, Brigham and Women's Hospital | Initiation date: Sep 2025 --> Sep 2026
    Trial initiation date
    1m
    Repurposing antibiotics: A dual-action approach against bacteria-induced cancer. (PubMed, Cancer Pathog Ther)
    Antibiotics such as doxycycline, rifampicin, and azithromycin demonstrate anticancer properties by inhibiting angiogenesis, inducing apoptosis, and regulating key pathways including the interleukin (IL)-6 signaling pathway and autophagy-related pathways. By elucidating the pivotal role of biofilms in persistent infections and highlighting untapped therapeutic opportunities in antibiotic repurposing, this review underscores a transformative approach to cancer treatment. This article explores the potential of repurposing antibiotic drugs for cancer treatment and highlights the prospects of drug repurposing strategies.
    Review • Journal
    |
    IL6 (Interleukin 6)
    |
    rifampicin